{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:54:04Z","timestamp":1770540844876,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis delta virus (HDV) infection is the most severe form of viral hepatitis. Bulevirtide (BLV, Hepcludex<jats:sup>\u00ae<\/jats:sup>) is an HDV\/HBV entry inhibitor approved in June 2020 in the European Union for adult patients with chronic hepatitis delta (CHD) and compensated liver disease and positive HDV RNA viral load. This real\u2010life preliminary report described early virological efficacy and safety of BLV in six patients with CHD and compensated liver disease: four patients were treated with the combination of BLV (2\u00a0mg\/d in subcutaneous injection) and pegylated interferon (PEG\u2010IFN) and two patients with BLV monotherapy. Four patients treated with combined therapy had a decline of a minimum of 1\u00a0log<jats:sub>10<\/jats:sub> and 3\/3 of 2\u00a0log<jats:sub>10<\/jats:sub> of HDV\u2010VL at 12 and 24 weeks, respectively. One patient among four had stopped the treatment at 12 weeks because of thrombocytopenia and an HDV\u2010VL relapse was notified 24\u00a0weeks after treatment cessation. Three patients among four (3\/4) had undetectable HDV\u2010VL during the therapy (&lt;100\u00a0IU\/ml). One patient (1\/2) treated with BLV monotherapy had a decline of HDV\u2010VL by 1\u00a0log<jats:sub>10<\/jats:sub> at 8 weeks and 1\/1 by 2\u00a0log<jats:sub>10<\/jats:sub> at 28 week on\u2010treatment. Two patients among four (2\/4) with combined therapy had normal ALT reached at 4 and 56 weeks. One patient (1\/2) with BLV monotherapy achieves ALT normalization at\u200b 4 weeks on treatment. Hepatitis B surface antigen (HBsAg) levels remain unchanged. Three among six (3\/6) patients had an elevation of total biliary acids without pruritus. These early data generated confirm the interest in this new treatment. Final results will be important to demonstrate long\u2010term clinical benefit (fibrosis reversibility and reduction in hepato\u2010cellular carcinoma [HCC]).<\/jats:p>","DOI":"10.1111\/liv.14950","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T14:56:58Z","timestamp":1621263418000},"page":"1509-1517","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real\u2010life"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-0595","authenticated-orcid":false,"given":"Tarik","family":"Asselah","sequence":"first","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7860-8636","authenticated-orcid":false,"given":"Dimitri","family":"Loureiro","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9deric","family":"Le Gal","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie Clinique Centre National de r\u00e9f\u00e9rence des H\u00e9patites B, C et Delta Universit\u00e9 de Paris 13 Inserm U955 AP\u2010HP H\u00f4pital Avicenne Bobigny France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Narguet","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-7730","authenticated-orcid":false,"given":"S\u00e9gol\u00e8ne","family":"Brichler","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie Clinique Centre National de r\u00e9f\u00e9rence des H\u00e9patites B, C et Delta Universit\u00e9 de Paris 13 Inserm U955 AP\u2010HP H\u00f4pital Avicenne Bobigny France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Bouton","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Universit\u00e9\u0301 de Paris AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malek","family":"Abazid","sequence":"additional","affiliation":[{"name":"Service de Pharmacie Universit\u00e9\u0301 de Paris AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Boyer","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Giuly","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athenais","family":"Gerber","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie Clinique Centre National de r\u00e9f\u00e9rence des H\u00e9patites B, C et Delta Universit\u00e9 de Paris 13 Inserm U955 AP\u2010HP H\u00f4pital Avicenne Bobigny France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-3489","authenticated-orcid":false,"given":"Issam","family":"Tout","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Maylin","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie Universit\u00e9 de Paris AP\u2010HP H\u00f4pital Saint\u2010Louis Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheikh M.","family":"Bed","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-0287","authenticated-orcid":false,"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Castelnau","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Gordien","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie Clinique Centre National de r\u00e9f\u00e9rence des H\u00e9patites B, C et Delta Universit\u00e9 de Paris 13 Inserm U955 AP\u2010HP H\u00f4pital Avicenne Bobigny France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-5771","authenticated-orcid":false,"given":"Abdellah","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Centre de recherche sur l'inflammation Universit\u00e9\u0301 de Paris Inserm U1149 CNRS ERL8252 Paris France"},{"name":"Department of Hepatology AP\u2010HP H\u00f4pital Beaujon Clichy France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.997"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30190-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30663-7"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_8_9_1","unstructured":"European Medicines Agency.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex. Accessed May 25 2021"},{"key":"e_1_2_8_10_1","unstructured":"ATU\/RTU \u2010 BULEVIRTIDE 2\u00a0mg poudre pour solution injectable \u2010 ANSM.https:\/\/www.ansm.sante.fr\/tableau\u2010atu\u2010rtu\/bulevirtide\u20102\u2010mg\u2010poudre\u2010pour\u2010solution\u2010injectable. Accessed May 25 2021"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30141-0"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2003.07.001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28772"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29574"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12735"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.04.004"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.03.017"},{"key":"e_1_2_8_19_1","unstructured":"Research C for DE and Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment Guidance for Industry. U.S. Food and Drug Administration. Published October 31 2019.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/chronic\u2010hepatitis\u2010d\u2010virus\u2010infection\u2010developing\u2010drugs\u2010treatment\u2010guidance\u2010industry. Accessed May 25 2021."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.06.038"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21325"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix656"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70409-9"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.003"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","unstructured":"LoureiroD CastelnauC ToutI et al.New therapies for hepatitis delta virus infection.Liver International. in press2021.","DOI":"10.1111\/liv.14838"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30058-1"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14950","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14950","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:38:08Z","timestamp":1693417088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/liv.14950"],"URL":"https:\/\/doi.org\/10.1111\/liv.14950","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2021-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}